Clinical Trial Update: Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating zoledronic acid in patients with renal cell carcinoma and bone metastases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Renal Cell Carcinoma

Drugs mentioned

• Zometa (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Cell Cancer, Neoplasm Metastasis | Phase 4 | Status: COMPLETED